Targeted antibodies in the treatment of lymphomas

Cancer Surveys

Volumn 30, Issue , 1997, Pages 295-309

  Falini, B ^a   Terenzi, A ^a   Liso, A ^a   Flenghi, L ^a   Solinas, A ^a   Pasqualucci, L ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOLIPID; GLYCOPROTEIN; IMMUNOTOXIN;

ANTIGEN ANTIBODY COMPLEX; BINDING AFFINITY; CATALYSIS; CYTOTOXICITY; EFFECTOR CELL; HYBRIDOMA; LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSEUDOMONAS; RADIOIMMUNOTHERAPY; REVIEW; TARGET CELL;

ANIMALS; HUMANS; IMMUNOTOXINS; LYMPHOMA; MICE; RADIOIMMUNOTHERAPY;

EID: 0030865181     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Amlot PL, Stone MJ, Cunningham D et al. (1993) A phase I study of an anti-GD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82 2624-2633
2. Barth S, Schnell R, Diehl V and Engert A (1996) Development of immnnotoxins for potential clinical use in Hodgkin's disease. Annals of Oncology 7 (Supplement 4) 9135-9141
3. Eary JF, Press OW, Badger CC et al. (1990) Imaging and treatment of B-cell lymphoma. Journal of Nuclear Medicine 31 1257-1268
4. Eiklid K, Olsnes S and Pihl A (1980) Entry of lethal doses of abrin, ricin and modecin into the cytosol of HeLa cells. Experimental Cell Research 126 321-326
5. Endo Y, Mitsui K, Motizuki M and Tsurugi K (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. Journal of Biological Chemistry 262 5908-5912
6. Engert A, Burrows F, Jung W et al. (1990a) Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Research 50 84-88
7. Engert A, Martin G, Pfreundschuh M et al. (1990b) Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumours in mice. Cancer Research 50 2929-2935
8. Engert A, Martin G, Amlot P et al. (1991) Immunotoxins constructed with anti-GD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumor effects against human Hodgkin cells in vitro and in solid Hodgkin tumors in mice. International Journal of Cancer 49 450-456
9. Falini B, Flenghi L, Fedeli L et al. (1992a) In vivo targeting of Hodgkin and Reed-Stemberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. British Journal of Haematology 82 38-45
10. Falini B, Bolognesi A, Flenghi L et al. (1992b) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339 1195-1197
11. Falini B, Pasqualucci L, Flenghi L et al. (1993) Therapy of refractory Hodgkin's disease with anti-CD30/saporin immunotoxin. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland [Abstract 90]
12. Falini B, Pileri S, Pizzolo G et al. (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85 1-14
13. 389/IL-2 in patients with NHL, HD and CTCL. Fourth International Symposium on Immunotoxins, Myrtle Beach, South Carolina, p 159
14. Frankel AE (ed). (1988), Immunotoxins, Kluwer Academic Press, Boston, Massachusetts
15. Ghetie MA, May RD, Till M et al. (1988) Evaluation of ricin A chain-containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Research 48 2610-2617
16. Ghetie V, Thorpe P, Ghetie MA et al. (1991a) The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulphide bond. Journal of Immunology Methods 142 223-230
17. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr J and Vitetta ES (1991b) Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human lymphoma-B grown in mice with severe combined immunodeficient disease: effect on tumor cells in extranodal sites. Cancer Research 51 5876-5880
18. Ghetie MA, Tucker K, Richardson J, Uhr J and Vitetta ES (1992) The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80 2315-2320
19. Ghetie MA, Tucker K, Richardson J, Uhr J and Vitetta ES (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84 702-707
20. Goldenberg DM, Larson SM, Reisfeld RA and Schlom J (1995) Targeting cancer with radiolabeled antibodies. Immunology Today 16 261-264
21. Gottestein C, Winkler U, Bohlen H, Diehl V and Engert A (1994) Immunotoxins: is there a clinical value ? Annals of Oncology 5 (Supplement 1) S97-S103
22. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID and Nadler LM (1992a) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80 863-878
23. Grossbard ML, Freedman AS, Ritz J et al. (1992b) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79 576-585
24. Grossbard ML, Lambert JM, Goldmacher VS et al. (1993a) Anti-B4-blocked ricin: a phase I trial of 7 day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology 11 726-737
25. Grossbard ML, Gribben JG, Freedman AS et al. (1993b) Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81 2263-2271
26. Grossbard ML, O'Day S, Gribben JG et al. (1994) A phase II study of anti-B4-blocked ricin (anti-B4-bR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin's lymphoma (B-NHL). Proceedings of the American Society of Clinical Oncology 13 293
27. Jansen B, Uckun FM, Jaszcz WB et al. (1992) Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43) pokeweed antiviral protein immunotoxin. Cancer Research 52 406-412
28. 131anti-B1 (anti-CD20) antibody. New England Journal of Medicine 329 459-465
29. Köhler C and Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 495-497
30. Lambert JM, Goldmacher VS, Collinson AR Nadler LM and Blattler WA (1991) An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Research 51 6236-6242
31. Pai LH and Pastan I (1993) Immunotoxin therapy of cancer. Journal of the American Medical Association 269 78-81
32. Pasqualucci L, Flenghi L, Terenzi A et al. (1995a) Immunotoxin therapy of hematological malignancies. Haematologica 80 546-556
33. Pasqualucci L, Wasik M, Teicher BA et al. (1995b) Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 85 2139-2146
34. Press OW, Eary JF, Badger CC et al. (1989) Treatment of refractory non-Hodgkin's lymphoma radiolabeled MB-1 (anti-CD37) antibody. Journal of Clinical Oncology 7 1027-1010
35. Press O W, Eary JF, Martin P et al. (1996) Radioimmunotherapy of B cell lymphomas. Annals of Oncology 7 33
36. Sausville PA, Headlee D, Stetler-Stevenson M et al. (1995) Continuous infusion of the anti CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 85 3457-3465
37. Stirpe F and Barbieri L (1986) Ribosome-inactivating proteins up to date. FEBS Letter 195 1-8
38. Stirpe F, Barbieri L, Battelli MG, Soria M and Lappi DA (1992) Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology 10 405-412
39. Stone MJ, Sausville EA, Fay JW et al. (1996) A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88 1188-1197
40. Tazzari PL, Bolognesi A, De Totero D et al. (1992) Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. British Journal of Haematology 81 203-211
41. 486/IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73 1276-1285
42. Terenzi A, Pasqualucci L, Flenghi L et al. (1994) In vivo antitumor activity of anti-CD22/RIPs 1 immunotoxins against disseminated Daudi B-cell lymphoma in SCID mice. Haematologica 74 (Supplement 4) 146a
43. Thorpe PE, Wallace PM, Knowles PP et al. (1988) Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Research 48 6396-6403
44. Uckun FM (1995) Fourth International Symposium on Immunotoxins, Myrtle Beach, South Carolina, p 162
45. Uckun FM, Manivel C, Arthur D et al. (1992a) In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 79 2201-2214
46. + human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 79 3116-3129
47. Uckun FM, Evans WE, Forsyth CJ et al. (1995) Biotherapy of B-cell precursor leukemia by targeting genistein to CD19 associated kinases. Science 267 886-891
48. Vallera DA (1994) Immunotoxins: will their clinical promise be fulfilled? Blood 83 309-317
49. Vitetta ES, Fulton RJ, May RD, Till M and Uhr J (1987) Redesigning nature's poison to create anti-tumor reagents. Science 238 1098-1104
50. Vitetta ES, Stone M, Amlot PL et al. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Research 51 4052-4058
51. Vitetta ES, Thorpe PE and Uhr JW (1993) Immunotoxins: magic bullets or misguided missiles? Immunology Today 14 252-259
52. Waldmann T, White JD, Carrasquillo JA et al. (1995) Radioimmunotherapy of interleukin-2RI-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 11 4063-4075
53. Winkler U, Gottstein C, Schon G et al. (1994) Successful treatment of disseminated human Hodgkin's disease in SGID mice with deglycosylated ricin A-chain immunotoxins. Blood 83 466-475